Nucana Plc ADR (NCNA)

$1.55 -0.05 (-3.13%)
Market Cap 6.45M
Revenue (ttm) 0.00
Net Income (ttm) -38.71M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 81,900
Avg Vol 41,338
Day's Range N/A - N/A
Shares Out 4.16M
Stochastic %K 19%
Beta 2.18
Analysts Strong Buy
Price Target $25.00

Company Profile

NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer in the United States. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company is developing medicines to overcome the limitations of nucleoside analogs and generate concentrations of anti-cancer metabolites in cancer cells. Its pipeline includes NUC-3373, a chemical entity derived from the nucleoside...

Industry: Biotechnology
Sector: Healthcare
Phone: 44 13 1357 1111
Address:
3 Lochside Way, Edinburgh, United Kingdom
ElginOnST
ElginOnST Jun. 26 at 7:41 PM
$INLF - it took over $VOD record volume. Coming after $NCNA volune from last year and hopefully $ADTX volume.
0 · Reply
ElginOnST
ElginOnST Jun. 26 at 4:59 PM
$INLF - look at that volume! It'll pass $VOD guiness record today. It'll come for $NCNA record from last year. May even come for $ADTX volume sometime next week. This is far from over.
0 · Reply
GreenEnergy1
GreenEnergy1 Jun. 26 at 11:47 AM
$NCNA Wow, so glad we finally left this POS. big mouth bulls gotta be loving this 🤣🤣🤣🤣
1 · Reply
FickleFin
FickleFin Jun. 25 at 1:49 PM
$NCNA with dead stocks like these..easy to short. Problem no volume. Just sucker retail.
1 · Reply
liiigachaaa
liiigachaaa Jun. 25 at 11:42 AM
$NCNA will run
0 · Reply
nkalargyros
nkalargyros Jun. 25 at 12:04 AM
$NCNA im in
0 · Reply
Skinner12345
Skinner12345 Jun. 24 at 4:17 PM
$NCNA we’ll be fine, just hold for 25 years 🚀
0 · Reply
bills7765
bills7765 Jun. 24 at 3:54 PM
$NCNA Bloss canceled his options so he can restructure at lower value when they dilute with resolutions. I expect more insiders to do this soon. I hope im wrong. Between insiders that dont care about shareholder value and crooked market makers, I dont see much hope rn. From this point can future growth offset dilution?
2 · Reply
ChickenClaw
ChickenClaw Jun. 23 at 2:00 PM
$NCNA Somebodys Buying Chunks On The Open Market...
1 · Reply
ChickenClaw
ChickenClaw Jun. 22 at 3:56 PM
$NCNA
0 · Reply
Latest News on NCNA
NuCana appoints Ian Webster as CFO

2026-06-01T12:43:48.000Z - 27 days ago

NuCana appoints Ian Webster as CFO

NuCana Appoints Ian Webster as Chief Financial Officer

Jun 1, 2026, 8:00 AM EDT - 27 days ago

NuCana Appoints Ian Webster as Chief Financial Officer

NuCana Reports First Quarter 2026 Financial Results and Provides Business Update

May 14, 2026, 4:01 PM EDT - 6 weeks ago

NuCana Reports First Quarter 2026 Financial Results and Provides Business Update

NuCana Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Business Update

Mar 19, 2026, 4:01 PM EDT - 3 months ago

NuCana Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Business Update

NuCana appoints Bruce as COO

2026-01-06T13:16:19.000Z - 6 months ago

NuCana appoints Bruce as COO

NuCana Appoints Theresa Bruce as Chief Operating Officer

Jan 6, 2026, 8:00 AM EST - 6 months ago

NuCana Appoints Theresa Bruce as Chief Operating Officer

NuCana presents latest clinical data at ESMO 2025 on NUC-7738

2025-12-10T13:15:35.000Z - 7 months ago

NuCana presents latest clinical data at ESMO 2025 on NUC-7738

NuCana presents data at ESMO on NUC-7738

2025-12-10T13:05:39.000Z - 7 months ago

NuCana presents data at ESMO on NUC-7738

NuCana Presents Latest Data Demonstrating Clinical Activity and Favorable Safety for NUC-7738 in Patients with PD-1-Resistant Melanoma

Dec 10, 2025, 8:00 AM EST - 7 months ago

NuCana Presents Latest Data Demonstrating Clinical Activity and Favorable Safety for NUC-7738 in Patients with PD-1-Resistant Melanoma

NuCana Reports Third Quarter 2025 Financial Results and Provides Business Update

Nov 13, 2025, 4:01 PM EST - 8 months ago

NuCana Reports Third Quarter 2025 Financial Results and Provides Business Update

NuCana announces grant of composition-of-matter patent for NUC-7738 in China

2025-11-05T13:15:29.000Z - 8 months ago

NuCana announces grant of composition-of-matter patent for NUC-7738 in China

NuCana Announces Grant of Composition-of-Matter Patent for NUC-7738 in China

Nov 5, 2025, 8:00 AM EST - 8 months ago

NuCana Announces Grant of Composition-of-Matter Patent for NUC-7738 in China

NuCana presents data at ESMO 2025 for NUC-7738, PD-1 inhibitors

2025-10-19T21:10:12.000Z - 9 months ago

NuCana presents data at ESMO 2025 for NUC-7738, PD-1 inhibitors

NuCana announces publication of new data for NUC-3373

2025-10-14T12:16:01.000Z - 9 months ago

NuCana announces publication of new data for NUC-3373

NuCana compliant with all Nasdaq continued listing criteria

2025-09-05T12:10:43.000Z - 10 months ago

NuCana compliant with all Nasdaq continued listing criteria

NuCana Compliant with All Nasdaq Continued Listing Criteria

Sep 5, 2025, 8:00 AM EDT - 10 months ago

NuCana Compliant with All Nasdaq Continued Listing Criteria

NuCana to Present Data on NUC-7738's Synergy with PD-1 Inhibitors at the ESMO Congress 2025

Sep 3, 2025, 8:00 AM EDT - 10 months ago

NuCana to Present Data on NUC-7738's Synergy with PD-1 Inhibitors at the ESMO Congress 2025

NuCana Reports Second Quarter 2025 Financial Results and Provides Business Update

Aug 20, 2025, 4:05 PM EDT - 11 months ago

NuCana Reports Second Quarter 2025 Financial Results and Provides Business Update

NuCana PLC (ADR) trading halted, news pending

2025-08-08T23:50:31.000Z - 11 months ago

NuCana PLC (ADR) trading halted, news pending

NuCana announces ADS ratio change

2025-08-01T20:10:41.000Z - 11 months ago

NuCana announces ADS ratio change

NuCana Announces ADS Ratio Change

Aug 1, 2025, 4:05 PM EDT - 11 months ago

NuCana Announces ADS Ratio Change

NuCana cancels all outstanding Series A Warrants

2025-07-21T12:28:02.000Z - 1 year ago

NuCana cancels all outstanding Series A Warrants

NuCana Cancels All Outstanding Series A Warrants Following Strategic ATM Execution

Jul 21, 2025, 8:05 AM EDT - 1 year ago

NuCana Cancels All Outstanding Series A Warrants Following Strategic ATM Execution

NuCana Announces Plan to Implement ADS Ratio Change

Jul 11, 2025, 10:30 AM EDT - 1 year ago

NuCana Announces Plan to Implement ADS Ratio Change

NuCana Reports First Quarter 2025 Financial Results and Provides Business Update

Jun 2, 2025, 4:01 PM EDT - 1 year ago

NuCana Reports First Quarter 2025 Financial Results and Provides Business Update

NuCana prices 10.8M ADSs at 64.54c in registered direct offering

2025-05-06T12:42:54.000Z - 1 year ago

NuCana prices 10.8M ADSs at 64.54c in registered direct offering

NuCana files to sell 16.05M American Depositary Shares

2025-04-24T10:21:56.000Z - 1 year ago

NuCana files to sell 16.05M American Depositary Shares

NuCana reports Q4 loss per share GBP (0.01) vs GBP (.14)

2025-03-20T20:55:23.000Z - 1 year ago

NuCana reports Q4 loss per share GBP (0.01) vs GBP (.14)

NuCana Reports Q4 EPS GBP (1) vs. GBP (14)

2025-03-20T20:20:12.000Z - 1 year ago

NuCana Reports Q4 EPS GBP (1) vs. GBP (14)

NuCana Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Update

Mar 20, 2025, 4:01 PM EDT - 1 year ago

NuCana Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Update

Aurion Biotech Appoints Donald Munoz as Chief Financial Officer

Feb 10, 2025, 7:00 AM EST - 1 year ago

Aurion Biotech Appoints Donald Munoz as Chief Financial Officer

NuCana reports Q3 EPS (GBP 0.07) vs (GBP 0.13) last year

2024-11-25T12:05:13.000Z - 1 year ago

NuCana reports Q3 EPS (GBP 0.07) vs (GBP 0.13) last year

NuCana Reports Third Quarter 2024 Financial Results and Provides Business Update

Nov 25, 2024, 7:00 AM EST - 1 year ago

NuCana Reports Third Quarter 2024 Financial Results and Provides Business Update

NuCana announces initial data from Phase 1b/2 modular study of NUC-3373

2024-11-11T12:12:48.000Z - 1 year ago

NuCana announces initial data from Phase 1b/2 modular study of NUC-3373

NuCana Announces Encouraging Initial Data from Phase 1b/2 Modular Study of NUC-3373 in Combination with Pembrolizumab or Docetaxel

Nov 11, 2024, 7:00 AM EST - 1 year ago

NuCana Announces Encouraging Initial Data from Phase 1b/2 Modular Study of NUC-3373 in Combination with Pembrolizumab or Docetaxel

Baillie Gifford's Strategic Acquisition of NuCana PLC Shares

Oct 4, 2024, 12:03 PM EDT - 1 year ago

Baillie Gifford's Strategic Acquisition of NuCana PLC Shares

NuCana Announces Grant of Composition-of-Matter Patent for NUC-7738 in the United States

Sep 25, 2024, 4:01 PM EDT - 1 year ago

NuCana Announces Grant of Composition-of-Matter Patent for NUC-7738 in the United States

NuCana Presents Encouraging Data on NUC-7738 in Combination with Pembrolizumab in PD-1 Inhibitor Refractory and Resistant Melanoma Patients at the ESMO Congress 2024

Sep 14, 2024, 3:01 AM EDT - 1 year ago

NuCana Presents Encouraging Data on NUC-7738 in Combination with Pembrolizumab in PD-1 Inhibitor Refractory and Resistant Melanoma Patients at the ESMO Congress 2024

NuCana Announces Update for Phase 2 Randomized Colorectal Cancer Study

Aug 29, 2024, 4:01 PM EDT - 1 year ago

NuCana Announces Update for Phase 2 Randomized Colorectal Cancer Study

NuCana Reports Second Quarter 2024 Financial Results and Provides Business Update

Aug 15, 2024, 4:01 PM EDT - 2 years ago

NuCana Reports Second Quarter 2024 Financial Results and Provides Business Update

NuCana to Present at the Jefferies Global Healthcare Conference

May 30, 2024, 8:36 AM EDT - 2 years ago

NuCana to Present at the Jefferies Global Healthcare Conference

NuCana to Present at TD Cowen's 5th Annual Oncology Innovation Summit

May 21, 2024, 8:00 AM EDT - 2 years ago

NuCana to Present at TD Cowen's 5th Annual Oncology Innovation Summit

NuCana Reports First Quarter 2024 Financial Results and Provides Business Update

May 16, 2024, 4:01 PM EDT - 2 years ago

NuCana Reports First Quarter 2024 Financial Results and Provides Business Update

NuCana Regains Compliance with Nasdaq Minimum Bid Price Requirement

May 1, 2024, 4:01 PM EDT - 2 years ago

NuCana Regains Compliance with Nasdaq Minimum Bid Price Requirement

NuCana Presents Data at the AACR 2024 Annual Meeting Highlighting the Ability of NUC-7738 to Profoundly Alter Tumor Biology in a Paired Biopsy Clinical Study

Apr 9, 2024, 4:30 PM EDT - 2 years ago

NuCana Presents Data at the AACR 2024 Annual Meeting Highlighting the Ability of NUC-7738 to Profoundly Alter Tumor Biology in a Paired Biopsy Clinical Study

NuCana Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Business Update

Mar 20, 2024, 4:01 PM EDT - 2 years ago

NuCana Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Business Update

NuCana to Present at TD Cowen's 44th Annual Health Care Conference

Feb 27, 2024, 8:00 AM EST - 2 years ago

NuCana to Present at TD Cowen's 44th Annual Health Care Conference

NuCana Reports Third Quarter 2023 Financial Results and Provides Business Update

Nov 16, 2023, 4:01 PM EST - 2 years ago

NuCana Reports Third Quarter 2023 Financial Results and Provides Business Update

NuCana Announces Listing Transfer to Nasdaq Capital Market

Nov 10, 2023, 4:01 PM EST - 2 years ago

NuCana Announces Listing Transfer to Nasdaq Capital Market

NuCana to Present at the Jefferies London Healthcare Conference

Nov 8, 2023, 4:01 PM EST - 2 years ago

NuCana to Present at the Jefferies London Healthcare Conference

NuCana to Participate in the Truist Securities 2023 BioPharma Symposium

Nov 1, 2023, 4:01 PM EDT - 2 years ago

NuCana to Participate in the Truist Securities 2023 BioPharma Symposium

NuCana Presents Promising Data on NUC-7738 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023

Oct 16, 2023, 7:00 AM EDT - 2 years ago

NuCana Presents Promising Data on NUC-7738 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023

NuCana Presents Encouraging Data on NUC-3373 in Colorectal Cancer at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023

Oct 13, 2023, 12:30 PM EDT - 2 years ago

NuCana Presents Encouraging Data on NUC-3373 in Colorectal Cancer at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023

NuCana Announces Presentations at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023

Sep 18, 2023, 8:00 AM EDT - 3 years ago

NuCana Announces Presentations at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023

NuCana Reports Second Quarter 2023 Financial Results and Provides Business Update

Aug 16, 2023, 4:01 PM EDT - 3 years ago

NuCana Reports Second Quarter 2023 Financial Results and Provides Business Update

NuCana to Present at the Jefferies Healthcare Conference

Jun 1, 2023, 8:00 AM EDT - 3 years ago

NuCana to Present at the Jefferies Healthcare Conference

NuCana Reports First Quarter 2023 Financial Results and Provides Business Update

May 17, 2023, 4:01 PM EDT - 3 years ago

NuCana Reports First Quarter 2023 Financial Results and Provides Business Update

NuCana Announces Receipt of Nasdaq Notice

May 12, 2023, 4:01 PM EDT - 3 years ago

NuCana Announces Receipt of Nasdaq Notice

NuCana Presents Data at the AACR 2023 Annual Meeting Highlighting Novel NUC-7738 Mechanisms of Action

Apr 14, 2023, 8:00 AM EDT - 3 years ago

NuCana Presents Data at the AACR 2023 Annual Meeting Highlighting Novel NUC-7738 Mechanisms of Action

NuCana Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Business Update

Apr 4, 2023, 4:01 PM EDT - 3 years ago

NuCana Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Business Update

Technical Board of Appeal of the European Patent Office Issues Oral Ruling that NuCana's ‘190 Patent is Not Valid

Mar 24, 2023, 4:30 PM EDT - 3 years ago

Technical Board of Appeal of the European Patent Office Issues Oral Ruling that NuCana's ‘190 Patent is Not Valid

NuCana to Participate in Two Upcoming Investor Conferences

Feb 28, 2023, 8:00 AM EST - 3 years ago

NuCana to Participate in Two Upcoming Investor Conferences

NuCana Announces Receipt of NASDAQ Notice

Jan 6, 2023, 4:01 PM EST - 3 years ago

NuCana Announces Receipt of NASDAQ Notice

NuCana Reports Third Quarter 2022 Financial Results and Provides Business Update

Nov 16, 2022, 4:01 PM EST - 3 years ago

NuCana Reports Third Quarter 2022 Financial Results and Provides Business Update

NuCana Presents Positive Data on NUC-3373 at the 34th EORTC-NCI-AACR Annual Meeting 2022

Oct 26, 2022, 7:00 AM EDT - 3 years ago

NuCana Presents Positive Data on NUC-3373 at the 34th EORTC-NCI-AACR Annual Meeting 2022

NuCana Presents Promising Data on NUC-7738 at the European Society of Medical Oncology (ESMO) Annual Meeting 2022

Sep 12, 2022, 10:45 AM EDT - 4 years ago

NuCana Presents Promising Data on NUC-7738 at the European Society of Medical Oncology (ESMO) Annual Meeting 2022

NuCana Announces Presentations at the European Society for Medical Oncology (ESMO) Congress 2022

Sep 6, 2022, 8:00 AM EDT - 4 years ago

NuCana Announces Presentations at the European Society for Medical Oncology (ESMO) Congress 2022

ElginOnST
ElginOnST Jun. 26 at 7:41 PM
$INLF - it took over $VOD record volume. Coming after $NCNA volune from last year and hopefully $ADTX volume.
0 · Reply
ElginOnST
ElginOnST Jun. 26 at 4:59 PM
$INLF - look at that volume! It'll pass $VOD guiness record today. It'll come for $NCNA record from last year. May even come for $ADTX volume sometime next week. This is far from over.
0 · Reply
GreenEnergy1
GreenEnergy1 Jun. 26 at 11:47 AM
$NCNA Wow, so glad we finally left this POS. big mouth bulls gotta be loving this 🤣🤣🤣🤣
1 · Reply
FickleFin
FickleFin Jun. 25 at 1:49 PM
$NCNA with dead stocks like these..easy to short. Problem no volume. Just sucker retail.
1 · Reply
liiigachaaa
liiigachaaa Jun. 25 at 11:42 AM
$NCNA will run
0 · Reply
nkalargyros
nkalargyros Jun. 25 at 12:04 AM
$NCNA im in
0 · Reply
Skinner12345
Skinner12345 Jun. 24 at 4:17 PM
$NCNA we’ll be fine, just hold for 25 years 🚀
0 · Reply
bills7765
bills7765 Jun. 24 at 3:54 PM
$NCNA Bloss canceled his options so he can restructure at lower value when they dilute with resolutions. I expect more insiders to do this soon. I hope im wrong. Between insiders that dont care about shareholder value and crooked market makers, I dont see much hope rn. From this point can future growth offset dilution?
2 · Reply
ChickenClaw
ChickenClaw Jun. 23 at 2:00 PM
$NCNA Somebodys Buying Chunks On The Open Market...
1 · Reply
ChickenClaw
ChickenClaw Jun. 22 at 3:56 PM
$NCNA
0 · Reply
FickleFin
FickleFin Jun. 22 at 2:13 PM
$NCNA share price should be reversed. Nucanna has more of a diverse pipeline than $QNTM. Yet trading half of Quantum. Still both 💩 stocks. Difference is $QNTM already have shown their cards multiple of times.
1 · Reply
nkalargyros
nkalargyros Jun. 18 at 2:28 AM
$NCNA hang
0 · Reply
JimmyCashMoney
JimmyCashMoney Jun. 18 at 1:28 AM
$ADTX $NCNA was in this same position a year ago, look here.
3 · Reply
JimmyCashMoney
JimmyCashMoney Jun. 17 at 11:25 PM
$ADTX this reminds me of $NCNA from a few years ago
0 · Reply
MarketManStockWizzard
MarketManStockWizzard Jun. 17 at 5:13 PM
$ADTX $NCNA $JAGX $NCNA doing $100M atm offering $ADTX doing a $53M atm offering $JAGX doing $62.7mixed securities offering. Best wishes.
0 · Reply
Skinner12345
Skinner12345 Jun. 17 at 3:00 PM
$NCNA did the COO really acquire 132 MILLION shares in April??
1 · Reply
jerry_springer
jerry_springer Jun. 17 at 1:14 PM
$ADTX yes! Also $NCNA pumped from .02 to .2 and $JAGX from .05 to .3 last year These plays are ultra high risk/ultra high reward
2 · Reply
Skinner12345
Skinner12345 Jun. 16 at 8:13 PM
$NCNA AH news? 🚀
0 · Reply
TVanda00
TVanda00 Jun. 15 at 10:06 PM
$NCNA Chart looking kinda rough. Fridays inability to keep price up after the bulls defended it so well on Thursday made the moving averages all curl the wrong way.
0 · Reply
ChickenClaw
ChickenClaw Jun. 12 at 7:15 AM
$NCNA Overall Market
0 · Reply
FickleFin
FickleFin Jun. 12 at 2:10 AM
$NCNA
0 · Reply
GreenEnergy1
GreenEnergy1 Jun. 11 at 1:42 PM
$NCNA Just sold the last of our shares! Adios Amigos… enjoy the ride
3 · Reply